A-66

A-66
Drug name	A-66

A-66 is a small-molecule inhibitor developed for research on class I phosphoinositide 3-kinases and related signaling pathways. Initially reported in medicinal chemistry and pharmacology literature, it has been examined in biochemical assays and preclinical models for its selectivity profile, potency against target isoforms, and potential utility in oncology and metabolic disease research.

Chemical identity and synthesis

A-66 was disclosed with a defined chemical structure in medicinal chemistry reports discussing structure–activity relationships alongside contemporaneous agents such as GDC-0941, BYL719, TGX-221, and wortmannin. Synthetic routes described in the literature employ standard organic transformations similar to those used for compounds like LY294002 and ZSTK474, with multi-step sequences involving amide couplings, heterocycle construction, and selective functional-group manipulations akin to methods reported for idelalisib, duvelisib, and pictilisib. Spectroscopic characterization parallels approaches used for published probes such as BEZ235, BKM120, and PX-866, with nuclear magnetic resonance, mass spectrometry, and elemental analysis reported in the original disclosure alongside comparisons to structurally related inhibitors like copanlisib, alpelisib, and taselisib.

Pharmacology and mechanism of action

A-66 acts as an ATP-competitive inhibitor of class I phosphoinositide 3-kinase isoforms, with biochemical potency and isoform selectivity evaluated in assays that also characterize inhibitors such as idelalisib, alpelisib, buparlisib, and dactolisib. Cellular pharmacology studies compare its activity with compounds like BYL719, SAR245408, and GDC-0032 in signaling readouts downstream of receptor tyrosine kinases including epidermal growth factor receptor, insulin receptor, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor. Mechanistically, A-66 suppresses phosphorylation cascades involving AKT, mTOR, S6 kinase, and 4E-BP1 in cell lines and models previously used to profile inhibitors such as everolimus, temsirolimus, and rapamycin, and its effects on apoptosis and cell-cycle regulators have been contrasted with those induced by paclitaxel, doxorubicin, and cisplatin in combination studies reported in the literature.

Preclinical and clinical research

Preclinical evaluations of A-66 include in vitro potency determinations using human cancer cell lines and primary cells comparable to studies of trastuzumab, cetuximab, nilotinib, and imatinib, and in vivo efficacy studies in xenograft models analogous to those for sorafenib, sunitinib, and crizotinib. Reports describe tumor-growth inhibition, pharmacodynamic modulation, and combination strategies pairing A-66 with agents such as erlotinib, gefitinib, paclitaxel, and carboplatin, mirroring approaches used in trials of bevacizumab, pembrolizumab, nivolumab, and ipilimumab. While A-66 appears in pharmacology databases and conference abstracts, it lacks the extensive clinical trial record of drugs like pembrolizumab, nivolumab, trastuzumab, and bevacizumab; no phase III registration studies analogous to those for imatinib, sorafenib, or sunitinib have been reported.

Pharmacokinetics and metabolism

Published preclinical pharmacokinetic data for A-66 report parameters measured in rodent and non-rodent species using bioanalytical methods also applied to agents such as midazolam, propranolol, warfarin, and sildenafil. Absorption, distribution, and clearance characteristics are compared in the literature with prototype kinase inhibitors including dasatinib, nilotinib, and lapatinib, with metabolic profiling describing oxidative and conjugative pathways similar to those observed for atorvastatin, simvastatin, and metformin in ADME studies. Plasma protein binding and tissue penetration have been evaluated using assays and models analogous to those employed for tamoxifen, fulvestrant, and letrozole, and in vitro studies using human liver microsomes and hepatocytes report involvement of cytochrome P450 isoforms as seen with midazolam, omeprazole, and clopidogrel.

Safety, tolerability, and toxicology

Toxicology investigations of A-66 include acute and repeat-dose studies in rodents and non-rodents with endpoints similar to those used for regulatory submissions of small-molecule kinase inhibitors such as sunitinib, sorafenib, and pazopanib. Observed safety signals have been contextualized alongside adverse-effect profiles reported for idelalisib, alpelisib, and buparlisib, with attention to hepatic enzyme elevations, hematologic changes, gastrointestinal effects, and metabolic perturbations like hyperglycemia akin to those documented with everolimus, sirolimus, and trametinib. Genotoxicity, reproductive toxicity, and safety-pharmacology assessments employ guidelines and study designs comparable to those used for nilotinib, imatinib, and dasatinib; no marketing authorization-level safety dossier equivalent to that for established therapeutics has been presented in the public literature.

Legal status and availability

A-66 is primarily a research compound referenced in academic publications, patents, and compound libraries rather than a licensed therapeutic product like imatinib, trastuzumab, pembrolizumab, or bevacizumab. Availability is typically through chemical suppliers, academic collaborations, and material-transfer agreements similar to arrangements for research tools such as CRISPR reagents, monoclonal antibodies, and small-molecule probes; it is not listed as an approved medicinal product by regulatory agencies analogous to the European Medicines Agency, Food and Drug Administration, or Pharmaceuticals and Medical Devices Agency. Patent filings and intellectual-property statements referencing A-66 appear alongside filings for other kinase inhibitors, but no marketing authorization comparable to those for established oncology drugs has been documented.

Category:Pharmacology Category:Kinase inhibitors